Shares of Axonics Inc. AXNX, -0.84% soared 19.2% toward a 13-month high in premarket trading Monday, after the medical technology company focused on treating urinary and bowel dysfunction announced an agreement to be acquired by Boston Scientific Corp. BSX, -0.02% in a cash deal with an equity value of about $3.7 billion. Under terms of deal, Boston Scientific will pay$71 for each Axonics shares outstanding, which represents a 23.3% premium to Friday’s closing price of $57.57. Boston Scientific’s stock tac ...